The widespread use of chemotherapy and the improvement in the survival rates of cancer patients has led to an increase in the cases of therapy-related leukemia. Therapy-related leukemias account for 10-20% of all cases of acute leukemia [1, 2] , with therapy-related AML (t-AML) and therapy-related MDS (t-MDS) being the most common types of therapy-related leukemia. However, therapy-related ALL (t-ALL) is rare, and only few cases of t-ALL have been reported in the literature [3, 4] . In one study, t-ALL was reported to account for 10% of all therapy-related leukemias and for less than 2% of all lymphoid leukemias [5] . Thus far, 8 cases of therapy-related leukemia following systemic chemotherapy have been reported in Korea; among these, 7 cases were of t-AML and 1 was of t-ALL with t(9;22)(q34;q11.2) [6] [7] [8] [9] [10] . We report a case of t-ALL with MLL gene rearrangement in a patient who had undergone treatment for breast cancer and review the related literature. ALL with MLL gene rearrangement secondary to chemotherapy has been rarely reported. We report a case of therapy-related ALL (t-ALL) with MLL gene rearrangement in a patient who had undergone treatment for breast cancer. A 60-yr-old woman with breast cancer underwent breastconserving surgery followed by 6 cycles of adjuvant chemotherapy (cyclophosphamide, epirubicin, and fluorouracil) and radiation therapy (dose, 5,040 cGy to the left breast and a 1,000 cGy boost to the tumor bed). A follow-up examination performed 14 months after the chemotherapy revealed no evidence of breast malignancy. However, the patient's complete blood cell count indicated acute leukemia: white blood cell count, 174.1×10 9 /L with 88% blasts; Hb level, 12.5 g/dL; and platelet count, 103.0×10 9 /L. Examination of the bone marrow aspirate smear revealed a high percentage of blasts (85.1% of all nucleated cells); the blasts showed a pro-B immunophenotype and were positive for CD19, CD79a, HLA-DR, CD34, and terminal deoxynucleotidyl transferase (TdT). Cytogenetic and FISH analyses revealed t(4;11)(q21;q23) and MLL gene rearrangement, respectively. The patient received induction chemotherapy with cyclophosphamide, vincristine, doxorubicin, and dexamethasone and achieved complete remission. Following consolidation chemotherapy, she underwent allogenic peripheral blood stem cell transplantation and has been clinically stable. To our knowledge, this is the first reported case of t-ALL with MLL gene rearrangement following treatment of breast cancer in Korea. (Korean J Lab Med 2010;30:255-9) 
INTRODUCTION
The widespread use of chemotherapy and the improvement in the survival rates of cancer patients has led to an increase in the cases of therapy-related leukemia. Therapy-related leukemias account for 10-20% of all cases of acute leukemia [1, 2] , with therapy-related AML (t-AML) and therapy-related MDS (t-MDS) being the most common types of therapy-related leukemia. However, therapy-related ALL (t-ALL) is rare, and only few cases of t-ALL have been reported in the literature [3, 4] . In one study, t-ALL was reported to account for 10% of all therapy-related leukemias and for less than 2% of all lymphoid leukemias [5] . Thus far, 8 cases of therapy-related leukemia following systemic chemotherapy have been reported in Korea; among these, 7 cases were of t-AML and 1 was of t-ALL with t(9;22)(q34;q11.2) [6] [7] [8] [9] [10] . We report a case of t-ALL with MLL gene rearrangement in a patient who had undergone treatment for breast cancer and review the related literature. 
CASE REPORT
A 60-yr-old woman with breast cancer underwent breast-conserving surgery followed by 6 cycles of adjuvant chemotherapy (cyclophosphamide, epirubicin, and fluorouracil) and radiation therapy (dose, 5,040 cGy to the left breast and a 1,000 cGy boost to the tumor bed).
A follow-up examination performed 14 months after the chemotherapy revealed no evidence of breast malignancy.
However, the patient' s complete blood cell count indi- 
DISCUSSION
The clinical and cytogenetic pathologies of therapy- [4] , have been reported [13] [14] [15] (Table 1) .
In all the 10 cases, including this case, patients were treated with regimens involving at least 1 topoisomerase II inhibitor. Although the latency period ranged from 10 months to 8 yr, the latency period in our case was short and less than 24 months. The leukemia cells in our case
showed an immature pro-B immunophenotype and were negative for CD10. This finding is consistent with that reported by Pagano et al. [5] , who compared 21 t-ALL cases with 695 de novo ALL cases [5] . They showed that the expression of B-cell and T-cell phenotypes in t-ALL and CD65 (Table 1) . Although the leukemia cells in this case showed the typical pro-B immunophenotype with CD10 negativity, these cells were not evaluated for aberrant expression of CD15 and CD65.
In cases of ALL with MLL rearrangement, especially t(4;11) translocation, the leukemia cells typically had a pro-B immunophenotype and were positive for CD19 and CD15 and negative for CD10 and CD24 [16] . Since all the 10 reported t-ALL cases had MLL rearrangements, the presence of CD10-negative cells with a pro-B immunophenotype and aberrant CD15 positivity may be a typical feature of ALL with MLL rearrangement, in the cases of both de novo ALL and t-ALL. However, in the series reported by Pagano et al. [5] , there was no correlation between the pro-B immunophenotype and any specific cytogenetic abnormality. The predominance of the pro-B immunophenotype may be related to both MLL rearrangement and therapy-related leukemogenesis.
The prognosis of t-AML is generally known to be poorer than that of de novo AML, and the survival rates of patients with secondary leukemia are difficult to predict because of the recurrence of the primary cancer. However, recent studies have shown that the outcome of t-AML treatment does not differ from that of de novo AML treatment after adjustment for unfavorable cytogenetic findings [17] . The outcome of t-ALL treatment has been assessed only in small series, and the survival rates and rates of complete remission in cases of t-AML were not different from those in cases of t-ALL [3, 18] .
Thus far, 8 cases of therapy-related leukemia, including 7 cases of t-AML and 1 case of t-ALL, have been reported in Korea [6] [7] [8] [9] [10] (Table 2 ). Similar to our case, the most 
